Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316074 | 0.76 | L3MBTL1 (0.52) | MAP4K4 | |
| SCHEMBL22590 | 0.76 | CYP17A1 (0.50) | MAP4K4CYP17A1NAMPTCA12CA1 | |
| SCHEMBL11180063 | 0.76 | CYP17A1 (0.42) | GSK3BDYRK1AATRMAP4K4CYP17A1 | |
| SCHEMBL971205 | 0.76 | GSK3B (0.40) | GSK3BDYRK1AATRMAP4K4CYP17A1 | |
| SCHEMBL6950030 | 0.75 | ATR (0.41) | GSK3BDYRK1AATRMAP4K4CYP17A1 | |
| SCHEMBL29695306 | 0.74 | NPC1 (0.58) | — | |
| SCHEMBL222110 | 0.74 | NPC1 (0.58) | — | |
| SCHEMBL6609814 | 0.73 | NAMPT (0.52) | GSK3BDYRK1AMAP4K4CYP17A1NAMPT | |
| SCHEMBL1126145 | 0.73 | RAB9A (0.62) | GSK3BDYRK1A | |
| SCHEMBL851343 | 0.73 | DEGS1 (0.56) | GSK3BDYRK1AGRIN2BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | claimed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | claimed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | claimed |
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-108347943-A | HEPATITIS B CORE PROTEIN MODULATORS | 组装生物科学股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-107922394-A | 3 tetrazole radical benzene, 1,2 disulfonic acid amide derivative as metal beta lactamase restrainer | 默沙东公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107849050-A | Compound | 爱丁堡大学董事会 | 2018-03-27 | — | — | CN | disclosed |
| CN-103459382-B | For suppressing the heterocyclic compound of PASK | 拜奥埃内杰尼克斯公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-103459382-A | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC | 2013-12-18 | — | — | CN | disclosed |
| US-7566716-B2 | Imidazopyrazines as Raf inhibitor compounds | ARRAY BIOPHARMA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1902056-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006125101-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-0958297-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999007704-A1 | 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR | SUNTORY LIMITED (JP) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281751-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | GSK3B 150/4885DYRK1A 951/4885ATR 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.